NCT02584842已完成不适用
Rivaroxaban for Thrombosis Prophylaxis in Endovenous Laser Ablation With and Without Miniphlebectomy: A Multicenter Experience
University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2012年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Number of patients with a EHIT class 3 or class 4 within 6 weeks after endovenous laser ablation
研究概览
简要总结
The purpose of this study is to determine retrospectively if the application of rivaroxaban after endovenous laser ablation with and without miniphlebectomy is safe and if it lowers the risk of venous thrombosis.
详细描述
Rivaroxaban is an orally active direct factor Xa inhibitor, that is used for thrombosis prophylaxis for example in the setting of orthopaedic surgery.
In the observed situation Rivaroxaban was applied in a dosage of 10mg daily during 5 days after endovenous laser ablation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age greater than 18 years, informed consent was given.
- •Endovenous Laser Ablation (EVLA) of the greater saphenous vein (GSV), autologous saphenous vein (ASV) and/or small saphenous vein (SSV) using 1470 nm wavelength radial laser (ELVeS, Biolitec, Austria) and postinterventional Endothermal Heat Induced Thrombosis (EHIT) prophylaxis with rivaroxaban.
排除标准
- •Patients are ineligible if they had:
- •an endovenous ablation technique other than EVLA,
- •other veins than GSV, ASV or SSV treated with EVLA (i.e. perforators),
- •postinterventional EHIT prophylaxis other than prophylactic dose of rivaroxaban or
- •informed consent was not given.
结局指标
主要结局
Number of patients with a EHIT class 3 or class 4 within 6 weeks after endovenous laser ablation
时间窗: within 6 weeks after endovenous laser ablation
次要结局
- Number of major or clinically relevant bleedings within 6 weeks after endovenous laser ablation.(within 6 weeks after endovenous laser ablation)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee ArthroscopyHaemorrhageVenous ThromboembolismNCT01629381University of Padova500
已完成
4 期
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With CancerRivaroxabanCancer-associated ThrombosisRecurrenceBleedingNCT01989845Seoul National University Hospital127
招募中
不适用
Rivaroxaban for Intracardiac Thrombosis in the Pediatric PopulationIntracardiac ThrombusNCT06371170Azienda Ospedaliero, Universitaria Ospedali Riuniti20
已完成
不适用
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)Treatment of Venous Thromboembolism in Cancer PatientsCancerVenous ThromboembolismNCT05461807Bayer2,437
已完成
3 期
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.Prevention of Venous ThromboembolismNCT03055026Fadoi Foundation, Italy582